Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

95 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Selective suppression of de novo SARS-CoV-2 vaccine antibody responses in patients with cancer on B cell-targeted therapy.
Azar JH, Evans JP, Sikorski MH, Chakravarthy KB, McKenney S, Carmody I, Zeng C, Teodorescu R, Song NJ, Hamon JL, Bucci D, Velegraki M, Bolyard C, Weller KP, Reisinger SA, Bhat SA, Maddocks KJ, Denlinger N, Epperla N, Gumina RJ, Vlasova AN, Oltz EM, Saif LJ, Chung D, Woyach JA, Shields PG, Liu SL, Li Z, Rubinstein MP. Azar JH, et al. Among authors: rubinstein mp. JCI Insight. 2023 Mar 22;8(6):e163434. doi: 10.1172/jci.insight.163434. JCI Insight. 2023. PMID: 36749632 Free PMC article.
Emerging Trends in Immunotherapy for Adult Sarcomas.
Husain M, Chen L, Liebner D, Beane J, Rubinstein M, Pollock R, Verschraegen C, Tinoco G. Husain M, et al. Oncologist. 2023 May 8;28(5):e233-e241. doi: 10.1093/oncolo/oyad052. Oncologist. 2023. PMID: 36905579 Free PMC article.
PD-1-Targeted Immunotherapy: The Ligand Matters.
Wieland A, Rubinstein MP, Li Z. Wieland A, et al. Among authors: rubinstein mp. J Immunol. 2023 Oct 1;211(7):1065-1066. doi: 10.4049/jimmunol.2300239. J Immunol. 2023. PMID: 37722094 No abstract available.
Postinfusion PD-1+ CD8+ CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphoma.
Denlinger N, Song NJ, Zhang X, Jeon H, Peterson C, Wang Y, Reynolds K, Bolz RM, Miao J, Song C, Wu D, Chan WK, Bezerra E, Epperla N, Voorhees TJ, Brammer J, Kittai AS, Bond DA, Sawalha Y, Sigmund A, Reneau JC, Rubinstein MP, Hanel W, Christian B, Baiocchi RA, Maddocks K, Alinari L, Vasu S, de Lima M, Chung D, Jaglowski S, Li Z, Huang X, Yang Y. Denlinger N, et al. Among authors: rubinstein mp. Blood Adv. 2024 Jun 25;8(12):3140-3153. doi: 10.1182/bloodadvances.2023012073. Blood Adv. 2024. PMID: 38607381 Free PMC article.
95 results